Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
6
86%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 3Large-scale testing
6(85.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 36 (85.7%)

Trials by Status

completed686%
terminated114%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_1

Effect of Azimilide Dihydrochloride on Renal Function

NCT00318838
completedphase_3

Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)

NCT00751738
terminatedphase_3

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)

NCT01464476
completedphase_3

Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.

NCT00035451
completedphase_3

Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators

NCT00035490
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00318838Phase 1

Effect of Azimilide Dihydrochloride on Renal Function

Completed
NCT00751738Phase 3

Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)

Completed
NCT01464476Phase 3

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)

Terminated
NCT00035451Phase 3

Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.

Completed
NCT00035490Phase 3

Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators

Completed
NCT00035464Phase 3

Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.

Completed
NCT00035477Phase 3

Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7